Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404244 | 0.89 | DHODH (0.56) | KDM4EALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL6410492 | 0.85 | TSHR (0.62) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL21446855 | 0.84 | KDM4E (0.77) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL6403580 | 0.84 | ALDH1A1 (0.53) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL6339040 | 0.79 | ELANE (0.62) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL266327 | 0.75 | CHEK1 (0.80) | KDM4EALDH1A1TSHRHSD17B10MAPT | |
| SCHEMBL7230026 | 0.75 | SIRT2 (0.72) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL4829005 | 0.75 | KDM4E (0.63) | KDM4EALDH1A1ALOX12TSHRHSD17B10 | |
| SCHEMBL6336997 | 0.74 | MAPT (0.66) | KDM4EALDH1A1TSHRHSD17B10MAPT | |
| SCHEMBL11045073 | 0.74 | F10 (0.77) | KDM4EALDH1A1TSHRHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | KDM4E 1406/4885ALDH1A1 1126/4885ALOX12 339/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | KDM4E 1879/4885ALDH1A1 1389/4885ALOX12 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.